XOMA Co. (NASDAQ:XOMA) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund grew its holdings in shares of XOMA Co. (NASDAQ:XOMA) by 51.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,362 shares of the biotechnology company’s stock after purchasing an additional 800 shares during the period. New York State Common Retirement Fund’s holdings in XOMA were worth $62,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of XOMA. Geode Capital Management LLC boosted its stake in XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after buying an additional 1,138 shares in the last quarter. Barclays PLC raised its stake in shares of XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares in the last quarter. State Street Corp raised its stake in shares of XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after acquiring an additional 1,754 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 1,699 shares in the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at XOMA

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 7.20% of the stock is currently owned by corporate insiders.

XOMA Trading Up 0.4 %

XOMA stock opened at $21.69 on Friday. The company has a market cap of $255.57 million, a P/E ratio of -6.23 and a beta of 0.90. XOMA Co. has a twelve month low of $20.87 and a twelve month high of $35.00. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The business has a fifty day moving average of $25.61 and a 200-day moving average of $27.81.

Analyst Ratings Changes

A number of research firms have issued reports on XOMA. HC Wainwright lowered their target price on XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a report on Monday, February 3rd. StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research note on Tuesday, February 25th.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.